Table 3.
Summary of DLTs
| Dose level | Age (years) | Gender | KPS, baseline | Primary site | Prior induction chemotherapy | DLT |
|---|---|---|---|---|---|---|
| 1 | 65 | M | 90 | BOT | No | Pneumonia, g.4 |
| 2 | 75 | F | 90 | SG larynx | No | CVA, g.4 |
| 2 | 71 | M | 80 | BOT | No | CHF, grade 3 |
| 3 | 73 | M | 90 | BOT | No | SVT, grade 3 |
| 4 | 55 | M | 80 | BOT | Yesa | Neuropathy, grade 3 |
| 4 | 65 | M | 100 | BOT | No | Dehydration, grade 3 and mucositis, grade 3 |
| 4 | 52 | F | 80 | Oral tongue | Yesb | Anemia, grade 3 |
aTP (docetaxel + cisplatin) + everolimus [16].
bTPF (docetaxel + cisplatin + 5-fluorouracil).
Abbreviations for primary site: BOT, base of tongue (oropharynx); SG, supraglottic.
Abbreviations for DLTs: CVA, cerebrovascular accident; CHF, congestive heart failure exacerbation; SVT, supraventricular tachycardia.